시장보고서

상품코드

1790309

미국의 mRNA 합성 원료 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 부문별 예측(2025-2033년)

U.S. mRNA Synthesis Raw Materials Market Size, Share & Trends Analysis Report By Type (Capping Agents, Nucleotides, Plasmid DNA, Enzymes), By Application (Vaccine Production, Therapeutics Production), By End Use, And Segment Forecasts, 2025 - 2033

발행일: 2025년 07월 | 리서치사:

Grand View Research | 페이지 정보: 영문 90 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

미국의 mRNA 합성 원료 시장 요약

미국의 mRNA 합성 원료 시장 규모는 2024년에 5억 4,100만 달러로 평가되었습니다. 2033년에는 9억 3,220만 달러에 달하고, 2025-2033년 6.57%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 이러한 성장의 배경에는 mRNA 기술에 대한 학계 및 산업계의 관심 증가, mRNA 연구에 대한 자금 지원 증가, mRNA 기반 백신의 장점에 대한 인식 증가 등이 있습니다.

또한, RNA 기술의 치료적 응용이 증가함에 따라 예측 기간 동안 mRNA 합성 원료에 대한 수요가 크게 증가할 것으로 예측됩니다.

유형 부문 대시보드
미국의 mRNA 합성 원료 시장 변수 분석
미국의 mRNA 합성 원료 시장 규모와 동향 분석(유형별, 2021-2033년)
캡핑제
- CleanCap 시약
- ARCA(Anti-Reverse Cap Analog)
- 기타
뉴클레오티드
- 수식 핵산
- 천연 핵산
플라스미드 DNA
효소
- 폴리메라아제
- RNase 억제제
- DNase
- 기타
기타

제5장 용도 비즈니스 분석

용도 부문 대시보드
미국의 mRNA 합성 원료 시장 용도 변동 분석
미국의 mRNA 합성 원료 시장 규모와 동향 분석(용도별, 2021-2033년)
치료제 제조
백신 제조
기타 용도

제6장 최종 용도 비즈니스 분석

최종 용도 부문 대시보드
미국의 mRNA 합성 원료 시장 최종 용도 변동 분석
미국의 mRNA 합성 원료 시장 규모와 동향 분석(최종 용도별, 2021-2033년)
바이오의약품 및 제약회사
CRO 및 CMO
학술연구기관

제7장 경쟁 구도

기업 분류
전략 매핑
기업 시장 현황 분석, 2024년
기업 개요/상장기업
- F. Hoffmann-La Roche Ltd.
- Jena Bioscience GmbH
- Merck KGaA
- Yeasen Biotechnology(Shanghai) Co., Ltd
- BOC Sciences
- Thermo Fisher Scientific, Inc.
- Maravai LifeSciences
- New England Biolabs
- Creative Biogene
- HONGENE
- Evonik Industries AG
- GENEVANT SCIENCES CORPORATION

LSH 25.08.25

U.S. mRNA Synthesis Raw Materials Market Summary

The U.S. mRNA synthesis raw materials market size was estimated at USD 541.0 million in 2024 and is projected to reach USD 932.2 million by 2033, growing at a CAGR of 6.57% from 2025 to 2033. This growth is attributed to the growing academic & industrial interest in mRNA technology, increasing funding for mRNA research, and rising awareness of the advantages of mRNA-based vaccines.

Moreover, the increasing therapeutic applications of RNA technology are anticipated to provide significant demand for the mRNA synthesis raw materials over the forecast period.

U.S. mRNA Synthesis Raw Materials Market Report Segmentation

This report forecasts revenue growth in the U.S. and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. mRNA synthesis raw materials market report based on type, application, and end use:

Type Outlook (Revenue, USD Million, 2021 - 2033)
Capping Agents
CleanCap Reagents
ARCA (Anti-Reverse Cap Analog)
Others
Nucleotides
Modified Nucleic Acids
- N1-methylpseudouridine-triphosphate
- 5-Methylcytidine triphosphate (5mCTP)
- Others
Natural Nucleic Acids
- Adenine
- Guanine
- Cytosine
- Uracil
Plasmid DNA
Enzymes
Polymerase
RNase Inhibitor
DNase
Others
Others
Application Outlook (Revenue, USD Million, 2021 - 2033)
Vaccine Production
Therapeutics Production
Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Biopharmaceutical & Pharmaceutical Companies
CROs & CMOs
Academic & Research Institutes

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
- 1.1.1. Type Segment
- 1.1.2. Application Segment
- 1.1.3. End Use Segment
1.2. Estimates and Forecast Timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Primary Research
1.5. Information or Data Analysis:
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objective

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. Growing academic & industrial interest in mRNA technology
  - 3.2.1.2. Advantages of mRNA vaccines
  - 3.2.1.3. Increasing funding for mRNA research
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. Nonexistence of effective government regulations for mRNA-based product approvals
  - 3.2.2.2. High cost of mRNA synthesis raw materials
- 3.2.3. Market Challenge Analysis
  - 3.2.3.1. Lack of long-lasting and affordable manufacturing processes
3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis

Chapter 4. Type Business Analysis

4.1. Type Segment Dashboard
4.2. U.S. mRNA Synthesis Raw Materials Market Type Movement Analysis
4.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
4.4. Capping Agents
- 4.4.1. Capping agents market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.4.2. CleanCap Reagents
  - 4.4.2.1. CleanCap reagents market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.4.3. ARCA (Anti-Reverse Cap Analog)
  - 4.4.3.1. ARCA (anti-reverse cap analog) market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.4.4. Others
  - 4.4.4.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)
4.5. Nucleotides
- 4.5.1. Nucleotides market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.5.2. Modified Nucleic Acids
  - 4.5.2.1. Modified nucleic acids market estimates and forecasts, 2021 - 2033 (USD Million)
  - 4.5.2.2. N1-methylpseudouridine-triphosphate
    - 4.5.2.2.1. N1-methylpseudouridine-triphosphate market estimates and forecasts, 2021 - 2033 (USD Million)
  - 4.5.2.3. 5-Methylcytidine triphosphate (5mCTP)
    - 4.5.2.3.1. 5-Methylcytidine triphosphate (5mCTP) market estimates and forecasts, 2021 - 2033 (USD Million)
  - 4.5.2.4. Others
    - 4.5.2.4.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.5.3. Natural Nucleic Acids
  - 4.5.3.1. Natural nucleic acids market estimates and forecasts, 2021 - 2033 (USD Million)
  - 4.5.3.2. Adenine
    - 4.5.3.2.1. Adenine market estimates and forecasts, 2021 - 2033 (USD Million)
  - 4.5.3.3. Guanine
    - 4.5.3.3.1. Guanine market estimates and forecasts, 2021 - 2033 (USD Million)
  - 4.5.3.4. Cytosine
    - 4.5.3.4.1. Cytosine market estimates and forecasts, 2021 - 2033 (USD Million)
  - 4.5.3.5. Uracil
    - 4.5.3.5.1. Uracil market estimates and forecasts, 2021 - 2033 (USD Million)
4.6. Plasmid DNA
- 4.6.1. Plasmid DNA market estimates and forecasts, 2021 - 2033 (USD Million)
4.7. Enzymes
- 4.7.1. Enzymes market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.7.2. Polymerase
  - 4.7.2.1. Polymerase market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.7.3. RNase Inhibitor
  - 4.7.3.1. RNase inhibitor market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.7.4. DNase
  - 4.7.4.1. DNase market estimates and forecasts, 2021 - 2033 (USD Million)
- 4.7.5. Others
  - 4.7.5.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)
4.8. Others
- 4.8.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Application Business Analysis

5.1. Application Segment Dashboard
5.2. U.S. mRNA Synthesis Raw Materials Market Application Movement Analysis
5.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Therapeutics Production
- 5.4.1. Therapeutics production market estimates and forecasts, 2021 - 2033 (USD Million)
5.5. Vaccine Production
- 5.5.1. Vaccine production market estimates and forecasts, 2021 - 2033 (USD Million)
5.6. Other Application
- 5.6.1. Other application market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. End Use Business Analysis

6.1. End Use Segment Dashboard
6.2. U.S. mRNA Synthesis Raw Materials Market End Use Movement Analysis
6.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
6.4. Biopharmaceutical & Pharmaceutical Companies
- 6.4.1. Biopharmaceutical & pharmaceutical companies market estimates and forecasts, 2021 - 2033 (USD Million)
6.5. CROs & CMOs
- 6.5.1. CROs & CMOs market estimates and forecasts, 2021 - 2033 (USD Million)
6.6. Academic & Research Institutes
- 6.6.1. Academic & research institutes market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Market Position Analysis, 2024
7.4. Company Profiles/Listing
- 7.4.1. F. Hoffmann-La Roche Ltd.
  - 7.4.1.1. Overview
  - 7.4.1.2. Financial Performance
  - 7.4.1.3. Product Benchmarking
  - 7.4.1.4. Strategic Initiatives
- 7.4.2. Jena Bioscience GmbH
  - 7.4.2.1. Overview
  - 7.4.2.2. Product Benchmarking
  - 7.4.2.3. Strategic Initiatives
- 7.4.3. Merck KGaA
  - 7.4.3.1. Overview
  - 7.4.3.2. Financial Performance
  - 7.4.3.3. Product Benchmarking
  - 7.4.3.4. Strategic Initiatives
- 7.4.4. Yeasen Biotechnology (Shanghai) Co., Ltd
  - 7.4.4.1. Overview
  - 7.4.4.2. Product Benchmarking
  - 7.4.4.3. Strategic Initiatives
- 7.4.5. BOC Sciences
  - 7.4.5.1. Overview
  - 7.4.5.2. Product Benchmarking
  - 7.4.5.3. Strategic Initiatives
- 7.4.6. Thermo Fisher Scientific, Inc.
  - 7.4.6.1. Overview
  - 7.4.6.2. Financial Performance
  - 7.4.6.3. Product Benchmarking
  - 7.4.6.4. Strategic Initiatives
- 7.4.7. Maravai LifeSciences
  - 7.4.7.1. Overview
  - 7.4.7.2. Financial Performance
  - 7.4.7.3. Product Benchmarking
  - 7.4.7.4. Strategic Initiatives
- 7.4.8. New England Biolabs
  - 7.4.8.1. Overview
  - 7.4.8.2. Product Benchmarking
  - 7.4.8.3. Strategic Initiatives
- 7.4.9. Creative Biogene
  - 7.4.9.1. Overview
  - 7.4.9.2. Product Benchmarking
  - 7.4.9.3. Strategic Initiatives
- 7.4.10. HONGENE
  - 7.4.10.1. Overview
  - 7.4.10.2. Product Benchmarking
  - 7.4.10.3. Strategic Initiatives
- 7.4.11. Evonik Industries AG
  - 7.4.11.1. Overview
  - 7.4.11.2. Financial Performance
  - 7.4.11.3. Product Benchmarking
  - 7.4.11.4. Strategic Initiatives
- 7.4.12. GENEVANT SCIENCES CORPORATION
  - 7.4.12.1. Overview
  - 7.4.12.2. Product Benchmarking
  - 7.4.12.3. Strategic Initiatives